facebook tracking
knowledge-service-img

Regulation/Guidelines

 Importer vs Indian Manufacturer Pathways for Biologicals in India: Key Regulatory Differences

One of the most consequential strategic decisions for any global Biological product company entering India is whether to proceed as an importer or establish local manufacturing. This decision has profound implications for Regulatory timelines, clinical data requirements, dossier expectations, commercial positioning, and long-term market competitiveness. India’s Regulatory framework under the […]

Read More

Regulation/Guidelines

Manufacturing License for Sale or for Distribution of Medical Devices in India: MD-3, MD-5, MD-7, and MD-9 Made Simple

India’s Medical Device manufacturing sector is growing rapidly, driven by a combination of government policy, the Make in India initiative, and increasing global demand for cost-effective, high-quality medical products. For any company wishing to manufacture Medical Devices in India — whether domestic or foreign — obtaining the correct manufacturing license […]

Read More

Regulation/Guidelines

Banned and Restricted Cosmetic Ingredients in India: The Updated List Every Global Brand Must Know

The Ingredient Compliance Imperative  For global Cosmetic brands, formulation approval in one major market — the EU, the US, or Japan is often viewed as a strong indicator of product safety and compliance. In India, this assumption can be costly. The Indian regulatory framework maintains its own list of banned and restricted Cosmetic ingredients, and […]

Read More
knowledge-service-img

Regulation/Guidelines

New Cosmetic in India? When and Why, You Need Form COS-3 and COS-12

The Pathway Most Brands Don’t Know Exists Many global Cosmetic brands first become aware of India’s novel ingredient approval requirements only after submitting their import registration application in Form COS-1 and receiving a query from the Central Drugs Standard Control Organisation (CDSCO). The reason is often straightforward: one or more […]

Read More
knowledge-service-img

Regulation/Guidelines

India’s Biological Regulatory Ecosystem Explained: CDSCO, RCGM, GEAC, DBT, NIB & Beyond

Why India’s Regulatory System is Different For companies entering India with Biological products for the first time, one of the most frequent surprises is the multiplicity of Regulatory authorities involved in approval, oversight, and commercialisation. Unlike the US FDA — a single agency with comprehensive jurisdiction over Biologics — India’s […]

Read More
knowledge-service-img

Regulation/Guidelines

CDSCO Online Portal (SUGAM) Guide for Drug Import Applications

Learn how to use the CDSCO SUGAM Portal for Drug Import applications in India. This guide explains registration, application submission, document requirements, and compliance steps for smooth regulatory approval. The CDSCO SUGAM Portal has transformed the Drug Import approval process in India by providing a centralized online platform for regulatory […]

Read More

Regulation/Guidelines

Loan License vs Own Manufacturing License in India: Which Route Is Right for Your Medical Device Business?

One of the most consequential decisions a Medical Device company faces when entering the Indian manufacturing landscape is whether to establish its own licensed manufacturing facility or to operate under a loan license arrangement. Both routes are fully legitimate under India’s Medical Devices Rules, 2017 (MDR 2017), and each carry […]

Regulation/Guidelines

Top 10 Reasons Biological Product Approvals Get Delayed in India — And How to Avoid Them

Time Is Money — And Preventable Delays Are Common India’s Biological product approval timelines are frequently longer than companies anticipate. While CDSCO has made significant progress in recent years — introducing electronic submissions, faster SEC meeting schedules, and more transparent communication — delays remain prevalent, and most of them are […]

Regulation/Guidelines

What Investors and PE Firms Actually Look for in Pharmaceutical Regulatory Due Diligence

Private equity investment in India’s Pharmaceutical sector has accelerated substantially. The combination of a large domestic market, globally competitive manufacturing, and India’s strategic position as a supplier of generic medicines to regulated markets worldwide has attracted significant capital from Domestic and International PE firms, strategic investors, and sovereign wealth funds. […]